Russell Investments Group Ltd. cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM) by 54.1% in the 2nd quarter, HoldingsChannel reports. The fund owned 41,533 shares of the medical device company’s stock after selling 48,936 shares during the period. Russell Investments Group Ltd.’s holdings in DexCom were worth $3,944,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of DXCM. UBS Group AG grew its position in shares of DexCom by 76.3% during the 1st quarter. UBS Group AG now owns 15,926 shares of the medical device company’s stock valued at $1,181,000 after acquiring an additional 6,890 shares during the period. JPMorgan Chase & Co. grew its position in shares of DexCom by 8.9% during the 1st quarter. JPMorgan Chase & Co. now owns 2,588,232 shares of the medical device company’s stock valued at $191,943,000 after acquiring an additional 211,250 shares during the period. Amalgamated Bank grew its position in shares of DexCom by 11.5% during the 2nd quarter. Amalgamated Bank now owns 20,404 shares of the medical device company’s stock valued at $1,938,000 after acquiring an additional 2,109 shares during the period. Chicago Capital LLC grew its position in shares of DexCom by 52.9% during the 2nd quarter. Chicago Capital LLC now owns 238,859 shares of the medical device company’s stock valued at $22,687,000 after acquiring an additional 82,646 shares during the period. Finally, First Trust Advisors LP grew its position in shares of DexCom by 139.4% during the 2nd quarter. First Trust Advisors LP now owns 219,701 shares of the medical device company’s stock valued at $20,867,000 after acquiring an additional 127,915 shares during the period.

In other news, VP Patrick Michael Murphy sold 2,372 shares of the firm’s stock in a transaction dated Monday, September 10th. The shares were sold at an average price of $143.69, for a total value of $340,832.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Richard Doubleday sold 2,581 shares of the firm’s stock in a transaction dated Monday, June 25th. The stock was sold at an average price of $98.58, for a total transaction of $254,434.98. Following the completion of the sale, the executive vice president now directly owns 94,429 shares of the company’s stock, valued at $9,308,810.82. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 207,322 shares of company stock valued at $23,856,914. Corporate insiders own 1.80% of the company’s stock.

DXCM has been the subject of a number of research reports. Piper Jaffray Companies increased their target price on shares of DexCom to $150.00 and gave the company an “overweight” rating in a research report on Thursday, August 2nd. Canaccord Genuity increased their target price on shares of DexCom from $125.00 to $150.00 and gave the stock a “buy” rating in a research note on Thursday, August 23rd. BidaskClub upgraded shares of DexCom from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, August 21st. Stephens increased their target price on shares of DexCom from $135.00 to $160.00 and gave the stock an “overweight” rating in a research note on Thursday, August 23rd. Finally, Robert W. Baird increased their target price on shares of DexCom from $140.00 to $160.00 and gave the stock a “positive” rating in a research note on Thursday, August 23rd. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $111.64.

NASDAQ:DXCM opened at $137.93 on Tuesday. DexCom, Inc. has a 12 month low of $42.62 and a 12 month high of $148.56. The company has a current ratio of 4.89, a quick ratio of 4.62 and a debt-to-equity ratio of 0.69.

DexCom (NASDAQ:DXCM) last posted its earnings results on Wednesday, August 1st. The medical device company reported ($0.10) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.18) by $0.08. DexCom had a negative net margin of 0.65% and a negative return on equity of 7.45%. The firm had revenue of $242.50 million during the quarter, compared to analysts’ expectations of $205.81 million. During the same period last year, the company posted ($0.16) EPS. The company’s quarterly revenue was up 42.1% compared to the same quarter last year. analysts anticipate that DexCom, Inc. will post -0.47 EPS for the current fiscal year.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Read More: Price to Earnings Ratio (PE) Basics

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.